Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
54.26
EV/EBITDA
52
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$--
EPS
$-54.7
Face value
--
Shares outstanding
1,569,110
CFO
$-55.46 Mln
EBITDA
$-63.68 Mln
Net Profit
$-212.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aethlon Medical (AEMD)
| -23.1 | 6.0 | -23.1 | -92.8 | -80.9 | -73.6 | -64.5 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aethlon Medical (AEMD)
| -96.0 | -60.4 | -20.5 | -84.9 | -24.7 | 156.5 | -96.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aethlon Medical (AEMD)
|
2.1 | 3.3 | 0.2 | -11.5 | -6,713.8 | -227.3 | -- | 0.5 |
| 7.9 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.6 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.7 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.5 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 75.9 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.2 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 117.1 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for... applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California. Address: 11555 Sorrento Valley Road, San Diego, CA, United States, 92121 Read more
Chief Operating Officer
Mr. Guy F. Cipriani BS (Eng.), MBA
Chief Operating Officer
Mr. Guy F. Cipriani BS (Eng.), MBA
Headquarters
San Diego, CA
Website
The share price of Aethlon Medical Inc (AEMD) is $2.13 (NASDAQ) as of 02-Apr-2026 15:30 EDT. Aethlon Medical Inc (AEMD) has given a return of -80.91% in the last 3 years.
Since, TTM earnings of Aethlon Medical Inc (AEMD) is negative, P/E ratio is not available.
The P/B ratio of Aethlon Medical Inc (AEMD) is 0.50 times as on 31-Mar-2026, a 83 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.01
|
|
2024
|
-0.04
|
0.08
|
|
2023
|
-0.01
|
0.01
|
|
2022
|
-0.02
|
0.01
|
|
2021
|
-0.04
|
0.03
|
The 52-week high and low of Aethlon Medical Inc (AEMD) are Rs 35.20 and Rs 1.36 as of 03-Apr-2026.
Aethlon Medical Inc (AEMD) has a market capitalisation of $ 3 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aethlon Medical Inc (AEMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.